Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes.

Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, O'Neil JP, Janabi M, Baker S, Lee SE, Perry DC, Bajorek L, Karydas A, Spina S, Grinberg LT, Seeley WW, Ramos EM, Coppola G, Gorno-Tempini ML, Miller BL, Rosen HJ, Jagust W, Boxer AL, Rabinovici GD.

Alzheimers Res Ther. 2019 Jan 31;11(1):13. doi: 10.1186/s13195-019-0470-7.

2.

CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.

Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL; AL-108-231 Investigators.

Neurology. 2018 Jan 23;90(4):e273-e281. doi: 10.1212/WNL.0000000000004859. Epub 2017 Dec 27.

3.

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.

Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C; Alzheimer’s Disease Neuroimaging Initiative, Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM.

Nature. 2017 Sep 28;549(7673):523-527. doi: 10.1038/nature24016. Epub 2017 Sep 20.

4.

Therapy and clinical trials in frontotemporal dementia: past, present, and future.

Tsai RM, Boxer AL.

J Neurochem. 2016 Aug;138 Suppl 1:211-21. doi: 10.1111/jnc.13640. Epub 2016 Jun 15. Review.

5.

Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.

Tsai RM, Lobach I, Bang J, Whitwell JL, Senjem ML, Jack CR Jr, Rosen H, Miller B, Boxer AL; AL-108-231 Investigators.

Parkinsonism Relat Disord. 2016 Jul;28:29-35. doi: 10.1016/j.parkreldis.2016.04.006. Epub 2016 Apr 24.

6.

Plasma neurofilament light chain predicts progression in progressive supranuclear palsy.

Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, Kramer JH, Rosen H, Miller BL, Zetterberg H, Boxer AL.

Ann Clin Transl Neurol. 2016 Feb 1;3(3):216-25. doi: 10.1002/acn3.290. eCollection 2016 Mar.

7.

Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.

Wang HF, Tan L, Cao L, Zhu XC, Jiang T, Tan MS, Liu Y, Wang C, Tsai RM, Jia JP, Yu JT; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2016;51(1):227-36. doi: 10.3233/JAD-150824.

PMID:
26836176
8.

The Chinese Verbal Learning Test specifically assesses hippocampal state.

Tsai RM, Leong JK, Dutt S, Chang CC, Lee AK, Chao SZ, Yokoyama JS, Tse M, Kramer JH, Miller BL, Rosen HJ.

Am J Alzheimers Dis Other Demen. 2015 Jun;30(4):412-6. doi: 10.1177/1533317514552667. Epub 2014 Sep 30.

9.

Treatment of frontotemporal dementia.

Tsai RM, Boxer AL.

Curr Treat Options Neurol. 2014 Nov;16(11):319. doi: 10.1007/s11940-014-0319-0.

10.

Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Tsai RM, Boxer AL.

Semin Neurol. 2014 Apr;34(2):225-34. doi: 10.1055/s-0034-1381739. Epub 2014 Jun 25. Review.

11.

A biotin-hydrogel-coated quartz crystal microbalance biosensor and applications in immunoassay and peptide-displaying cell detection.

Chen HM, Huang TH, Tsai RM.

Anal Biochem. 2009 Sep 1;392(1):1-7. doi: 10.1016/j.ab.2009.05.029. Epub 2009 May 22.

PMID:
19464992

Supplemental Content

Support Center